Lupin Ltd

BSE 500257 LUPIN INE326A01037

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals NIFTY 500

Filing rhythm · 30 trading days

21 filings · 12 material · busiest 2026-08-06

What it files

Press Release5 Analyst / Investor Meet3 General2 Investor Presentation2 AGM / EGM2 ESOP Allotment1 KMP1 Concall Transcript1

Filings

21 in the window

25 August 2026

ESOP Allotment

Allotment of ESOP / ESPS

Intimation of allotment of 30967 equity shares under ESOP.

Company Update / Allotment of ESOP / ESPS View filing →
24 August 2026

General

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - ESG Rating

ESG Rating by ESG Risk Assessment and Insights Limited.

Company Update / General View filing →
20 August 2026

General

Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A.

VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.

Company Update / General View filing →
18 August 2026

KMP

Demise

Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.

Company Update / Demise View filing →
17 August 2026

Press Release

Press Release / Media Release

Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.

Company Update / Press Release / Media Release View filing →
12 August 2026

Concall Transcript

Earnings Call Transcript

Transcript of Q1 FY2027 Earnings Conference Call

Company Update / Earnings Call Transcript View filing →
10 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Intimation about participating in the Analyst/Institutional Investors Meet.

Company Update / Analyst / Investor Meet View filing →
10 August 2026

Press Release

Press Release / Media Release

Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.

Company Update / Press Release / Media Release View filing →
7 August 2026

Investor Presentation

Investor Presentation

Investor Presentation (Revised) - Q1 FY27 Results

Company Update / Investor Presentation View filing →
7 August 2026

Analyst / Investor Meet

Analyst / Investor Meet - Outcome

Link of Audio recording of the Earnings Call-Q1 FY27.

Company Update / Analyst / Investor Meet View filing →
6 August 2026

Board Outcome

Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

Board Meeting / Outcome of Board Meeting View filing →
6 August 2026

Results

Board Meeting Outcome For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

Result / Financial Results View filing →
6 August 2026

Press Release

Press Release / Media Release

Lupin Q1 FY2027 Results

Company Update / Press Release / Media Release View filing →
6 August 2026

Investor Presentation

Investor Presentation

Investor Presentation- Q1 FY2027

Company Update / Investor Presentation View filing →
4 August 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.

AGM/EGM / AGM View filing →
4 August 2026

AGM / EGM

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer's Report.

AGM/EGM / AGM View filing →
31 July 2026

Press Release

Press Release / Media Release

Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection.

Company Update / Press Release / Media Release View filing →
31 July 2026

Press Release

Press Release / Media Release

Lupin Announces the approval of Diazepam Injection, USP in the United States.

Company Update / Press Release / Media Release View filing →
22 July 2026

Board Meeting

Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.

Lupin Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....

Board Meeting / Board Meeting View filing →
22 July 2026

Analyst / Investor Meet

Analyst / Investor Meet - Intimation

Schedule of Earnings Call for Q1 FY27

Company Update / Analyst / Investor Meet View filing →
21 July 2026

Acquisition

Acquisition

Lupin Inc. U.S.A., wholly owned subsidiary of the Company has entered into a licensing agreement in exchange of 332,000 Common Shares of Kaveri Therapeutics, Inc. U.S.A.

Company Update / Acquisition View filing →